Chronic Rhinitis
Conditions
Keywords
Rhinitis
Brief summary
The CLARITY Study is a prospective, single-arm, multicenter safety and efficacy study of the Neurent Medical NEUROMARK System in subjects with chronic rhinitis.
Interventions
DEVICENEUROMARK System
The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Sponsors
Neurent Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A prospective, single-arm, multicenter clinical study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject provides written informed consent, including authorization to release health information. * Subject is 18 years of age or older at the time of consent. * Subject has provided a negative pregnancy test (if subject is a woman of childbearing potential (WOCBP). * Subject WOCBP must be practicing and willing to continue an effective method of birth control during the course of the study. * Confirmation of moderate to severe symptoms of rhinorrhea. (VAS NSS score for runny nose ≥ 5.0 and rTNSS score for runny nose ≥ 2). * Confirmation of mild to severe symptoms of nasal congestion. (VAS NSS score ≥ 2.5 for stuffy nose (congestion) and rTNSS score of ≥ 1). * Confirmation that the total combined VAS NSS score is ≥ 10 for nasal congestion and runny nose. * Subjects stated willingness to comply with all study procedures, post- treatment care and availability for the duration of the study follow up of 1 year. * Subject tests negative for active COVID-19 at the start of study screening and continues to be free from COVID-19 symptoms until the time of enrollment/treatment. * Subject understands and agrees to follow local COVID-19 restrictions (social distancing, face mask, etc.). * Nasal anatomy appropriate to receive the NEUROMARK™ System. * Subject is experiencing long term chronic rhinitis. Subject has been experiencing symptoms of rhinitis for at least 6 months prior to enrollment, defined as: rhinorrhea, anterior runny nose AND congestion, blockage (stuffy nose, obstruction).
Exclusion criteria
* Subject has clinically significant anatomic obstruction that limits access to the posterior nose as determined by the Study Investigator such as severe septal deviation, prior surgical considerations, cleft palate, nasal polyps, or sino-nasal tumor. * Subject has an active nasal or sinus infection at the time of treatment. * Subject has a diagnosis of Atrophic Rhinitis. * Subject has a Lund-Mackay score \>3 during the screening phase, an active history of chronic sinusitis (within the last year). * Subject has a septal perforation or nasal mucosal erosion/ulceration. * Subject experiences numbness of the soft palate, excessive dry eye, excessive dry nose, or other indication of neuro/nerve compromise in the sino-nasal anatomy. * Subject has had prior sinus or nasal surgery that may prevent access or proper placement of the NEUROMARK™ System. * Subject has had prior head or neck irradiation (head/neck cancer therapy). * Subject has an allergy or intolerance to anaesthetic agent or other study-required materials. * Subject is taking anticoagulant medication or 325 mg aspirin that cannot be discontinued before the procedure and for the length of the study. * Subject has a history of nasal manifestation of rheumatic disease. * Subject has started a new sino-nasal medication regimen within 4 weeks prior to treatment (i.e. antihistamines, cromolyn, leukotriene receptor antagonists, inhaled or systemic steroids, anticholinergics, expectorants, decongestants) that, per the manufacturer's labelling, has not yet stabilized. * Subject has uncontrolled Hypothyroidism. * Subject has uncontrolled Hypertension (stage 2 or higher). * Subject is an active smoker or has been a smoker within the last 6 months (patient reported). * Any physical condition that in the Investigator's opinion would prevent adequate study participation or pose increased risk to the study Subject. * Subject is pregnant, nursing or plans to become pregnant during the study, or is a WOCBP, but is not willing to use an effective method of birth control. * Patient is enrolled in an investigational drug or device study or has participated in such a study within the last 30 days prior to screening that in the opinion of the Investigator would interfere with the study results. * Patient presents with any condition or situation which, in the Investigator's opinion, puts the Subject at risk, could confound the study results, or may interfere significantly with the Subject's participation in the study. * Subject presents with acute sinusitis at time of treatment or other sino-nasal related illness other than rhinitis. * Subject has history of chronic epistaxis or nosebleed episodes within the last 12 months. * Subject has rhinitis symptoms due to seasonal allergies only. * Subject has received previous procedure or surgery for chronic rhinitis and/or to disrupt the posterior nasal nerve.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Device- or Procedure-related Serious Adverse Events (SAEs) Within 1 Month | 1 month | SAEs were defined per ICH-GCP (E6). This measure includes all SAEs assessed by the investigator as related to the device and/or procedure within 1 month post-procedure. |
| Mean Change From Baseline in VAS Nasal Symptom Score (NSS) for Rhinorrhea at 3 Months | 3 months | The Visual Analog Scale Nasal Symptom Score (VAS NSS) is a patient-reported outcome measure of nasal symptom severity. Each symptom item is scored on a scale of 0 to 10, where 0 indicates no symptoms and 10 indicates the worst possible symptoms; higher scores indicate worse outcomes. This measure reports the mean change from baseline to 3 months in VAS NSS for \[rhinorrhea\]. A negative change from baseline indicates improvement. |
| Mean Change From Baseline in VAS Nasal Symptom Score (NSS) for Nasal Congestion at 3 Months | 3 months | The Visual Analog Scale Nasal Symptom Score (VAS NSS) is a patient-reported outcome measure of nasal symptom severity. Each symptom item is scored on a scale of 0 to 10, where 0 indicates no symptoms and 10 indicates the worst possible symptoms; higher scores indicate worse outcomes. This measure reports the mean change from baseline to 3 months in VAS NSS for \[nasal congestion\]. A negative change from baseline indicates improvement. |
Countries
United States
Contacts
STUDY_DIRECTORAnnalise Sorensen
Neurent Medical
Participant flow
Recruitment details
Participants with chronic rhinitis were enrolled in a prospective, single-arm study evaluating the NEUROMARK System.
Pre-assignment details
Participants who met eligibility criteria were enrolled and assigned to receive treatment with the NEUROMARK System. One participant was lost to follow-up after the 3-month visit.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 62.8 Years STANDARD_DEVIATION 14 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 32 Participants |
| Severity of Chronic Rhinitis Mild | 0 Participants |
| Severity of Chronic Rhinitis Moderate | 9 Participants |
| Severity of Chronic Rhinitis Severe | 27 Participants |
| Sex: Female, Male Female | 19 Participants |
| Sex: Female, Male Male | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 36 |
| other Total, other adverse events | 2 / 36 |
| serious Total, serious adverse events | 0 / 36 |
Outcome results
None listed